Caveolin‐1 is essential for metformin inhibitory effect on IGF1 action in non‐small‐cell lung cancer cells
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Metformin causes an AMP/ATP ratio increase and AMP‐activated protein kinase (AMPK) activation. Since caveolin‐1 (Cav‐1) plays a role in AMPK activation and energy balance, we investigated whether Cav‐1 could participate in metformin's inhibitory effect on IGF1 signaling. The effect of metformin was studied in two non‐small‐cell lung cancer (NSCLC) cell lines, Calu‐1 and Calu‐6, expressing higher and lower amounts of Cav‐1, respectively. In Calu‐1, but not in Calu‐6 cells, metformin reduced phosphorylation of type 1 insulin‐like growth factor receptor (IGF‐IR) substrates Akt and Forkhead transcription factor 3a (FOXO3a), inhibited IGF1‐dependent FOXO3a nuclear exit, and decreased IGF1‐dependent cell proliferation. Here, we show that sensitivity of NSCLC cells to metformin was dependent on Cav‐1 expression and that metformin required Cav‐1 to induce AMPK phosphorylation and AMP/ATP ratio increase. Cav‐1 silencing in Calu‐1 and overexpression in Calu‐6 reduced and improved, respectively, the inhibitory effect of metformin on IGF1‐dependent Akt phosphorylation. Prolonged metformin treatment in Calu‐6 cells induced a dose‐dependent expression increase of Cav‐1 and OCT1, a metformin transporter. Cav‐1 and OCT1 expression was associated with the antiproliferative effect of metformin in Calu‐6 cells (IC 50 =18 mM). In summary, these data suggest that Cav‐1 is required for metformin action in NSCLC cells.—Salani, B., Maffioli, S., Hamoudane, M., Parodi, A., Ravera, S., Passalacqua, M., Alama, A., Nhiri, M., Cordera, R., Maggi, D. Caveolin‐1 is essential for metformin inhibitory effect on IGF1 action in non‐small‐cell lung cancer cells. FASEB J. 26, 788–798 (2012). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“diabetes was linked to a lower risk of cancer (4, 5).”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“Therefore, metformin could represent a good candidate to inhibit cellular growth activated by IGF1 (19).”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“homeostasis in response to energy stress (10, 11).”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“circulating plasma glucose concentration (13, 14).”
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“The main metabolic effect of metformin is lowering of blood glucose concentrations, mainly resulting from inhibition of liver gluconeogenesis (2, 3).”
BackgroundBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Zakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213
OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects
Moreno-Navarrete, J. M., Ortega, F. J., Rodríguez-Hermosa, J.-I., Sabater, M., Pardo, G., Ricart, W., & Fernández-Real, J. M. (2011) · Diabetes · doi:10.2337/db10-0805 · Cited by 100 · cited 1×
“necessary for metabolic activities of metformin (9).”
Cited by
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Caveolin-1 in the regulation of cell metabolism: a cancer perspective
Nwosu, Z. C., Ebert, M. P., Dooley, S., & Meyer, C. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0558-7 · Cited by 256
Metformin Targets Multiple Signaling Pathways in Cancer
Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C.-N., Zhang, J., & Lu, Y. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0184-9 · Cited by 152
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
“…2011; Lamanna et al. 2011; Lee et al. 2011; Liu et al. 2011; Monami et al. 2011; Pasternak et al. 2011; Majumder et al. 2012; Roumie et al. 2012; Salani et al. 2012; Tseng 2012; Anisimov and Bartke 2013; Goldfine et al. 2013; Hong et al. 2013; Karnevi et al. 2013; Martin-Montalvo et al. 2013;…”
BackgroundEndosomal trafficking in metabolic homeostasis and diseases
Gilleron, J., & Zeigerer, A. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00737-9 · Cited by 57
Metadata
- Authors
- Salani, B., Maffioli, S., Hamoudane, M., Parodi, A., Ravera, S., Passalacqua, M., Alama, A., Nhiri, M., Cordera, R., & Maggi, D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2011-10-28
- Volume
- 26
- Issue
- 2
- Pages
- 788-798
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2104242851
- Cited by
- 73
- References
- 13
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.